Claes Karlsson

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: NATURE CANCER. 2022;3(2):251-261

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

Tamborero D; Dienstmann R; Rachid MH; Boekel J; Lopez-Fernandez A; Jonsson M; Razzak A; Braña I; De Petris L; Yachnin J; Baird RD; Loriot Y; Massard C; Martin-Romano P; Opdam F; Schlenk RF; Vernieri C; Masucci M; Villalobos X; Chavarria E; Cancer Core Europe consortium; Balmaña J; Apolone G; Caldas C; Bergh J; Ernberg I; Fröhling S; Garralda E; Karlsson C; Tabernero J; Voest E; Rodon J; Lehtiö J
Article: HAEMATOLOGICA. 2019;104(4):797-804

First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.

Sylvan SE; Asklid A; Johansson H; Klintman J; Bjellvi J; Tolvgård S; Kimby E; Norin S; Andersson P-O; Karlsson C; Karlsson K; Lauri B; Mattsson M; Sandstedt AB; Strandberg M; Österborg A; Hansson L
Article: LEUKEMIA. 2019;33(4):969-980

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Fraser G; Cramer P; Demirkan F; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy M-S; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Pavlovsky MA; Karlsson C; Hallek M; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Chanan-Khan A
Article: HAEMATOLOGICA. 2016;101(12):1573-1580

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.

Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
Article: LANCET ONCOLOGY. 2016;17(2):200-211

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy M-S; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M; HELIOS investigators
Article: ANNALS OF HEMATOLOGY. 2014;93(10):1725-1733

Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients.

Eketorp Sylvan S; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Article: LEUKEMIA & LYMPHOMA. 2014;55(8):1774-1780

Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region.

Eketorp Sylvan S; Hansson L; Karlsson C; Norin S; Lundin J; Osterborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2009;144(1):78-85

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.

Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
Article: LEUKEMIA. 2007;21(3):511-514

Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).

Karlsson C; Hansson L; Celsing F; Lundin J
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;135(4):475-485

Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.

Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Article: LEUKEMIA. 2004;18(3):484-490

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.

Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H

Alla övriga publikationer

Letter: ACTA ONCOLOGICA. 2023;62(6):560-564

The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results.

Smedby KE; Wästerlid T; Tham E; Haider Z; Joelsson J; Thorvaldsdottir B; Krstic A; Wahlin BE; Foroughi-Asl H; Karlsson C; Eloranta S; Saft L; Palma M; Kwiecinska A; Hansson L; Österborg A; Wirta V; Rassidakis G; Sander B; Sonnevi K; Rosenquist R
Corrigendum: NATURE CANCER. 2022;3(5):649

Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

Tamborero D; Dienstmann R; Rachid MH; Boekel J; Lopez-Fernandez A; Jonsson M; Razzak A; Braña I; De Petris L; Yachnin J; Baird RD; Loriot Y; Massard C; Martin-Romano P; Opdam F; Schlenk RF; Vernieri C; Masucci M; Villalobos X; Chavarria E; Cancer Core Europe consortium; Balmaña J; Apolone G; Caldas C; Bergh J; Ernberg I; Fröhling S; Garralda E; Karlsson C; Tabernero J; Voest E; Rodon J; Lehtiö J
Letter: NATURE MEDICINE. 2020;26(7):992-994

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal.

Tamborero D; Dienstmann R; Rachid MH; Boekel J; Baird R; Braña I; De Petris L; Yachnin J; Massard C; Opdam FL; Schlenk R; Vernieri C; Garralda E; Masucci M; Villalobos X; Chavarria E; Cancer Core Europe consortium; Calvo F; Fröhling S; Eggermont A; Apolone G; Voest EE; Caldas C; Tabernero J; Ernberg I; Rodon J; Lehtiö J
Letter: HAEMATOLOGICA. 2019;104(5):E208-E210

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.

Winqvist M; Andersson P-O; Asklid A; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Rosenquist R; Späth F; Hansson L; Österborg A; Swedish CLL Group
Meeting abstract: BLOOD. 2015;126(23):1745

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

Hansson L; Winqvist M; Asklid A; Andersson P-O; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Osterborg A
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2012;159(5):608-612

Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.

Sylvan SE; Rossmann E; Mozaffari F; Porwit A; Norin S; Karlsson C; Hansson L; Lundin J; Österborg A
Letter: BLOOD CANCER JOURNAL. 2011;1(6):e22

Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia.

Karlsson C; Dahl H; Lundin J; Rossmann E; Brytting M; Mellstedt H; Linde A; Osterborg A
Thesis / dissertation: 2010

Targeted monoclonal antibody therapy in chronic lymphocytic leukemia

Karlsson, Claes
Review: CURRENT HEMATOLOGIC MALIGNANCY REPORTS. 2009;4(1):47-53

Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.

Osterborg A; Karlsson C; Lundin J
Letter: LEUKEMIA. 2006;20(12):2204-2007

Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.

Karlsson C; Norin S; Kimby E; Sander B; Porwit Macdonald A; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
Editorial comment: MEDICAL ONCOLOGY. 2006;23(1):137-139

Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia.

Lundin J; Karlsson C; Celsing F
Meeting abstract: BLOOD. 2004;104(11):277A

Virus reactivation profile as assessed by PCR and serology pattern following first-line alemtuzumab (anti-CD52 monoclonal antibody, Campath®) therapy in patients with B-CLL.

Karlsson C; Dahl H; Linde A; Lundin J; Björkholm M; Mellstedt H; Osterborg A

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2024-2027

Examina och utbildning

Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2010
Läkarexamen, Karolinska Institutet, 1994

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI